about
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancerIn vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profileRecent advances in the in silico modelling of UDP glucuronosyltransferase substrates.Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.Comparison data sets for benchmarking QSAR methodologies in lead optimization.Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.Is urinary indolyl-3-acryloylglycine a biomarker for autism with gastrointestinal symptoms?Gastrointestinal microbiota and metabolite biomarkers in children with autism spectrum disorders.Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years.Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches.Towards integrated ADME prediction: past, present and future directions for modelling metabolism by UDP-glucuronosyltransferases.Pharmacists in Australian general practice: an opportunity for expertise in precision medicineIncreased abundance of Sutterella spp. and Ruminococcus torques in feces of children with autism spectrum disorder.Targeted pharmacotherapy after somatic cancer mutation screening.A review of candidate urinary biomarkers for autism spectrum disorder.Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia.Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics.Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.Risk-difference curves can be used to communicate time-dependent effects of adjuvant therapies for early stage cancer.Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis.The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies--a systematic review.Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?Exploration of the perceptions, barriers and drivers of pharmacogenomics practice among hospital pharmacists in Adelaide, South Australia.Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort.Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug-Drug Interactions Involving Modafinil.Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis.Comparison of linear and nonlinear classification algorithms for the prediction of drug and chemical metabolism by human UDP-glucuronosyltransferase isoforms.Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis.Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?Targeted arginine metabolomics: A rapid, simple UPLC-QToF-MS(E) based approach for assessing the involvement of arginine metabolism in human disease.Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes.Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.Consumer-pharmacist interactions around complementary medicines: agreement between pharmacist and consumer expectations, satisfaction and pharmacist influence.Is there a role for routinely screening children with autism spectrum disorder for creatine deficiency syndrome?
P50
Q27027648-D6D1B0C0-84B4-4B9E-9D12-1272A30ACCCAQ28472573-A093C82C-F7D2-45AF-9FF6-06E8337CDE0AQ30367367-666EB0BE-AD13-4C2D-A526-33C8BD7BDDF1Q31102468-F6E18246-F33F-47EE-9ECE-8C72DF02416AQ33477047-34DEBABD-1D7C-4291-B776-BE3C0FAF7ECEQ34981428-FA8A139D-8E6C-4ECC-AF25-33767D449007Q34998738-B8DBF976-9B9B-4AE9-BDAF-38FD3AF31F0DQ35142420-880A09A8-E4C0-4AC8-8C64-BEF935D0887AQ35224179-FB8F1FB2-CA7B-41C6-835D-1B50F85CDBFFQ35639092-7BDC27C7-0607-43BA-99B4-62466A6F2DFFQ35795506-A5923DB6-E463-4188-88E9-6513A22565B3Q36114697-07DFEA90-8F0F-4E58-B07C-AF3D0ECD1A7FQ37308368-013EEBE3-F411-45A6-9C66-FE8E6EC96814Q37595442-108F6E75-BA7E-4FF4-BE0C-5658F0EFC405Q37948828-48BEADA9-A1E6-44C5-9A61-3A22DF97FA35Q38097339-7B92078C-2D45-4CC4-9386-C7FB41C54F47Q38106616-974E2B75-7D3D-4C1D-ADB4-7D6A4B3A0A24Q38107524-7BEE1321-AD00-45DF-95E1-4A6126DD397AQ38202816-898A6CEF-2C9D-418E-A557-4C11B1B87B38Q38209238-B96CC67F-E786-4B64-9EA5-7F77BEB1A45FQ38239192-1FD1DB45-10B7-4923-B7C9-2EEE54539CBAQ38254564-271D8079-8EB0-408C-BCF1-F0839D2F20D3Q38357969-484B7DC0-A907-459F-B62A-9BD452ABC6B0Q38915072-D8390FD5-F067-4291-AB8C-9B86524EBCAFQ38937228-4DF4DD29-FD48-4A53-9C28-50AAF7C8B6EDQ39150032-C2E8309E-F63E-45B8-AADB-EE0E080FA211Q39353238-288A2447-6667-4EC2-8187-5AED91D767DCQ39596343-907F40E9-3FBB-4D42-949C-280BD52DB54EQ39906127-C5D85BEB-5B71-4381-8635-A6EEF341C2AFQ39939059-E2F39938-42CF-4C54-A75E-8D1AEF795E0CQ40182957-69DD439F-099E-41FD-B18D-071A9A751FCCQ40547925-FB5C7967-575C-4811-8535-678FEDC1D7F2Q40578433-7F188CE1-CEE3-45D4-800E-D144DD3D3A76Q40847456-36282165-F05B-427E-9727-76085CB5CA57Q40887486-A320C10A-0B5A-4EF1-AC1A-FA4F8A652D4FQ41035635-484A98E9-D19F-4D1D-96AD-5798ADD92734Q41764396-814295FE-A736-45FA-A108-560A10A3D808Q41899044-E800386F-8280-46A7-B2EB-0F46B100F946Q42693172-CC485879-BCB0-403F-A43E-14A73AF472C7Q42999980-8DEB1E95-2E1E-4A15-9F20-23E5FF433C4B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michael J. Sorich
@ast
Michael J. Sorich
@en
Michael J. Sorich
@es
Michael J. Sorich
@nl
Michael J. Sorich
@sl
type
label
Michael J. Sorich
@ast
Michael J. Sorich
@en
Michael J. Sorich
@es
Michael J. Sorich
@nl
Michael J. Sorich
@sl
prefLabel
Michael J. Sorich
@ast
Michael J. Sorich
@en
Michael J. Sorich
@es
Michael J. Sorich
@nl
Michael J. Sorich
@sl
P1053
A-1210-2011
P106
P1153
6603262691
P21
P2456
P31
P3829
P496
0000-0003-1999-866X